Shares of Anthera Pharmaceuticals Inc. slipped over 58% in extended trading on Tuesday in the wake of its phase III trial of Sollpura in cystic fibrosis patients with exocrine pancreatic insufficiency falling short of expectations.
from RTT - Biotech http://ift.tt/2hrNpFH
via IFTTT
No comments:
Post a Comment